Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients treated with FEC100-taxotere and FEC100-taxotere-herceptin

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

  FEC100-taxotere FEC100-taxotere-herceptin
N = 118 %a N = 46 %a
Tumor type
Ductal carcinoma 106 89.9 44 95.6
Lobular carcinoma 7 5.9 1 2.2
Other 5 4.2 1 2.2
Tumor size
T0-T1 5 4.3 1 2.3
T2 60 51.7 21 48.8
T3 24 20.7 11 25.6
T4 27 23.3 10 23.3
NA 2 1.7 3 6.5
Histoprognostic grade
SBRI 7 6.7 1 2.5
SBRII 54 51.9 19 47.5
SBRIII 43 41.3 20 50
NA 14 11.9 6 13.1
Nodal status
Positive 63 54.3 30 65.2
Negative 53 45.7 16 34.8
NA 2 1.7 0 0
Hormone receptor status
Positiveb 77 66.3 23 50.0
Negativec 39 33.6 23 50.0
NA 2 1.7 0 0.0
HER-2 status
Positived 5 4.7 46 100.0
Negative 102 95.3 0 0.0
NA 11 9.3 0 0.0
Clinical response
CR 11 12.2 7 21.9
PR 62 68.9 23 71.9
SD 15 16.7 2 6.3
PD 2 2.2 0 0.0
NA 28 23.7 14 30.4
pCR
Yes 25 21.2 18 40.0
No 93 78.8 27 60.0
NA 0 0.0 1 2.2
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not applicable, pCR pathological complete response.
  2. aPercentages of evaluable patients (except for NA: percentage of all patients).
  3. bEstrogen receptor or progesterone receptor positive.
  4. cEstrogen receptor and progesterone receptor negative.
  5. dIHC3+ or IHC2+/FISH+ or CISH+.